Should You Buy SMR While It's Under $20?

NuScale Power (NYSE: SMR), a small modular nuclear reactor developer, has seen its share price plunge more than 58% over the past six months, closing just above $17 on Dec. 16 after a 52-week high of $57 in October and a decline of over 20% in the last month. The company remains commercially unproven and is still trying to finalize its first customer agreements — including a partnership with ENTRA1 — with material revenue visibility unlikely before 2027; analyst skepticism and investor stake trimming are weighing on the stock. Although the broader nuclear resurgence and projected energy demand from AI data centers present a long-term growth thesis, near-term execution risk and uncertain customer commitments keep the outlook cautious for investors.

Analysis

Market structure: NuScale (SMR) sits at the intersection of a revived nuclear demand cycle (AI data centers, baseload-hungry industry) and classic project-development economics: winners are well‑capitalized utilities, EPC contractors, uranium producers (CCJ/URA) and AI hyperscalers that secure long‑duration offtakes; losers are pre‑revenue developers without binding contracts. Competitive dynamics favor incumbents with balance‑sheet scale — NuScale’s pricing power is constrained until it converts pilot deals into paid milestones; absence of signed offtakes through 2026 preserves downside risk and keeps peers’ bargaining leverage high.

Risk assessment: Tail risks include NRC/licensing setbacks, a >30% project cost overrun, or lost DOE/utility funding that could force equity raises at deeply dilutive levels; these are low‑probability but would wipe out common equity. Time horizons: days–weeks will be dominated by sentiment swings and volatility; months (by 6–12 months) hinge on commercial offtake announcements and DOE/ENTRA milestones; 2027+ is the real value‑creation window for revenue recognition. Hidden dependencies: critical forgings, long lead times in heavy fabrication, and utility creditworthiness — any bottleneck amplifies capex and timing risk.

Trade implications: Size optionality — small equity exposure plus asymmetric options is the efficient way to play SMR: small direct long (2–3%) for optionality, plus cheap LEAP calls to capture re‑rate if 1–2 offtakes are announced by end‑2026. Relative trades: overweight AI beneficiaries (NVDA) vs underweight SMR as a volatility/realization trade; rotate capital into uranium producers (e.g., CCJ or URA) to capture commodity upside without project‑execution risk. Catalysts to watch that will move positions: binding offtake/EPC contracts, NRC design certifications, and DOE tranche awards — treat each as a binary rerating event.

Contrarian angles: The market may be over‑penalizing SMR for timing risk while underestimating concentrated demand from AI data centers that need predictable baseload; a single 100–200 MW offtake could re‑rate equity multiples 2x–3x versus current depressed levels. Historical parallels: early wind/solar OEMs traded at penny‑levels pre‑contract then exploded on firm PPAs — the asymmetry exists but is contingent on verifiable commercial traction. Unintended consequence: policy subsidies could preferentially flow to larger incumbents, crowding out smaller SMR players and compressing expected returns even if nuclear demand grows.

Key Decisions for Investors

• Establish a tactical 2–3% long position in NuScale Power (SMR) only if entry price remains < $20; set a hard stop‑loss at 40% from entry and plan to add an incremental 1–2% only after a signed offtake/EPC contract is publicly announced (target: by 31‑Dec‑2026).
• Buy asymmetric optional exposure: purchase SMR Jan 17, 2027 LEAP calls strike $25 (or nearest available) sized to 0.5% of portfolio notional to capture upside if commercialization milestones hit in 2026–2027; cap loss to premium paid and exit if no material progress by 1‑Jan‑2027.
• Implement a pair trade: overweight NVIDIA (NVDA) +1–2% vs benchmark (play AI demand) and short SMR equal‑dollar 0.5–1% to express faster realization of AI power demand versus NuScale’s commercialization risk; rebalance positions after major milestones (NRC docket entries or DOE awards) or quarterly on 30‑Jun‑2025.
• Rotate 1–2% capital into uranium exposure (e.g., CCJ or URA ETF) as a lower execution‑risk play on nuclear resurgence; simultaneously trim 1% exposure to early‑stage renewable installers with weak balance sheets to free funding for the SMR optionality trade.